Last updated: May 29, 2026

Application No. 18/457,729

BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP

Final Rejection

Filed

Aug 29, 2023

Priority

Apr 01, 2020 — EU 20167624.4 +1 more

Examiner

AEDER, SEAN E

Art Unit

1642

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Hoffmann-La Roche, Inc.

OA Round

2 (Final)

This examiner grants 57% of cases after interview

— +19.6% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1406 resolved cases, 2023–2026

Examiner Intelligence

AEDER, SEAN E View full profile →

Grants 57% of resolved cases

Career Allowance Rate

800 granted / 1406 resolved

-3.1% vs TC avg

Strong +20% interview lift

Without

With

+19.6%

Interview Lift

resolved cases with interview

Typical timeline

3y 0m

Avg Prosecution

61 currently pending

Career history

1483

Total Applications

across all art units

Statute-Specific Performance

§101

15.3%

-24.7% vs TC avg

§103

31.9%

-8.1% vs TC avg

§102

12.5%

-27.5% vs TC avg

§112

18.0%

-22.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1406 resolved cases

Prosecution Timeline

Aug 29, 2023

Application Filed

Feb 09, 2026

Non-Final Rejection mailed

Apr 27, 2026

Response Filed

May 06, 2026

Final Rejection mailed

May 07, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

17/762,703

Patent 12631644

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

4y 1m to grant Granted May 19, 2026

18/025,640

Patent 12629396

APPLICATION OF BACTERIA IN PREPARATION OF SYNERGIST FOR IMMUNE CHECKPOINT INHIBITOR

3y 2m to grant Granted May 19, 2026

17/998,795

Patent 12617845

SMC1A ANTIBODIES AND USES THEREOF

3y 5m to grant Granted May 05, 2026

17/769,245

Patent 12613245

METHODS FOR DETECTING AND INHIBITING BRAIN METASTASIS

4y 0m to grant Granted Apr 28, 2026

18/007,859

Patent 12612449

HIV-1 ANTIBODIES

3y 4m to grant Granted Apr 28, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

57%

Grant Probability

76%

With Interview (+19.6%)

3y 0m (~3m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1406 resolved cases by this examiner. Grant probability derived from career allowance rate.